$0.98
+0.02(1.78%)
Mkt Cap $24M
$0.67
$1.82
52-Week Range
At a Glance
AI-generatedEnlivex Therapeutics Ltd.
6-K
Enlivex Therapeutics Ltd. reported that the Rain Foundation launched an OpenClaw and AI agent interface enabling anyone to create live prediction markets via a single prompt without coding or gatekeepers, and announced a $5 million grant program for developers. As a major RAIN token holder, Enlivex views this as enhancing Rain's position and potential revenue growth via 2.5% trading volume buy-and-burn.$24M
Market Cap
—
Revenue
-$13M
Net Income
Employees71
Fundamentals
How The Business Makes Money
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001596812
ISINIL0011319527
CUSIPM4130Y106
Phone972 8 662 3301
Address14 Einstein Street, Ness Ziona, 7403618, IL
SEC EDGAR